Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies @dfocosi @MoritzGerstung @shay_fleishon @PeacockFlu @RajlabN @JosetteSchoenma @C_A_Gustave @LongDesertTrain @siamosolocani https://t.co/jdn9XT7kw3
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Nov 2022 – May 2023Where it's discussed
-
X / Twitter27 posts
-
YouTube2 videos
-
Facebook2 posts
-
News2 articles
AI synopsis
What people are saying
Overall, discussions demonstrate high agreement and interest, with posts describing the findings as warning signs for vaccine efficacy and treatment failures, using terms like 'concerning' and 'critical' to underscore the potential public health implications. The tone reflects a sense of urgency and focus on the importance of ongoing research and adaptation of medical strategies.
Most discussions acknowledge the significance of the study, emphasizing the immune evasion capabilities of these subvariants.
Participants display high interest, frequently referencing the mutations and the implications for treatment effectiveness.
Many posts delve into technical details, suggesting a moderate level of engagement, with some sharing links and specific antibody efficacy data.
The discussions highlight considerable concern over the potential impact on vaccine and treatment strategies, indicating perceived high impact.
Abstract in brief
- The convergent evolution of SARS-CoV-2 Omicron lineages has resulted in new subvariants like BA.2.75.2, BA.4.6, and BQ.1.1, with BQ.1.1 becoming dominant globally by December 2022.
- These subvariants exhibit mutations in the spike protein that enhance their transmissibility and ability to evade immune responses.
- Research indicates that many monoclonal antibodies (mAbs), including Ronapreve and Evusheld, show reduced effectiveness against these subvariants, with neutralizing antibody levels remaining low in fully vaccinated individuals, raising concerns about current treatment options in vaccinated populations.
Top posts
Most liked on X and BlueskyResistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/k3CHU39TZA #bioRxiv
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/JWKDfQXLc4
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies | bioRxiv https://t.co/tKLXsgYHdM
@IritBerman וחדשות עוד יותר טובות לאלו עם מערכת חיסונית מוחלשת המתחסנים עם החיסון הביוולנטי, שכן תתי הווריאנטים החדשים מתחמקים מהחיסון הפסיבי עם הנוגדנים המונוקלונלים הקיימים. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/2mXA2MXvkV
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/5HV0XWN0oM #biorxiv_micrbio
All mentions
Resistance of Omicron Subvariants to Neutralizing Antibodies Explained
This video discusses recent findings on the resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies, highlighting the challenges in treatment due to mutations that reduce antibody…
Omicron Subvariants BA.2.75.2, BA.4.6, and BQ.1.1 Resistance to Neutralizing Antibodies
The convergent evolution of SARS-CoV-2 Omicron lineages has resulted in new subvariants like BA.2.75.2, BA.4.6, and BQ.1.1, with BQ.1.1 becoming dominant globally by December 2022. These subvariants exhibit mutations in…
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies - PMC https://t.co/U1acuWzOJk
Trend new: Planas D, ..., Schwartz O (Nat Commun) __Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies__ https://t.co/FF1rZezRp4
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies https://t.co/0gAncdqmCR
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/lPtYHTO3mU
Delphine Planas, Timothee Bruel, Isabelle Staropoli, et al. and Olivier Schwartz. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. bioRxiv 2022.11.17.516888; doi: https://t.co/4X5U7tdeJi https://t.co/FsTBh7wS5Z
New preprint: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/REbftk9M1K #COVID19
RT @RolandBakerIII: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/JWKDfQXLc4
RT @RolandBakerIII: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/JWKDfQXLc4
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/JWKDfQXLc4
RT @ejustin46: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies @dfocosi @MoritzGerstung @shay_fle…
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/5EeM57th71 ...
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/5EeM57tOWz ...
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies | bioRxiv https://t.co/tKLXsgYHdM
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/QQlVEo18Lj
RT @ejustin46: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies @dfocosi @MoritzGerstung @shay_fle…
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/2fRkKLd0KB
AFD Blog `Preprint: Resistance of #Omicron Subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to Neutralizing Antibodies' https://t.co/g6xw8eYl4Z
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, BQ.1.1 to nAbs: (Casirivimab & Imdevimab) & (Cilgavimab & Tixagevimab) lost any antiviral efficacy against BA.2.75.2, BQ.1.1, (Sotrovimab) remained weakly active. BQ.1.1 & resistant to Bebtelovimab. https://t.co/ARoSFrCAWs
Resistance of #Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing #antibodies - #Ronapreve (#Casirivimab and #Imdevimab) and #Evusheld (#Cilgavimab and #Tixagevimab) lost any #antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas #Xevudy…https://t.co/4CB9DlclmH
@IritBerman וחדשות עוד יותר טובות לאלו עם מערכת חיסונית מוחלשת המתחסנים עם החיסון הביוולנטי, שכן תתי הווריאנטים החדשים מתחמקים מהחיסון הפסיבי עם הנוגדנים המונוקלונלים הקיימים. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/2mXA2MXvkV
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies @dfocosi @MoritzGerstung @shay_fleishon @PeacockFlu @RajlabN @JosetteSchoenma @C_A_Gustave @LongDesertTrain @siamosolocani https://t.co/jdn9XT7kw3
RT @GuzmanQCarlos: Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies | bioRxiv https://t.co/6QnUlRl…
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies | bioRxiv https://t.co/6QnUlRlykJ
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/RXL8SRyArN
Preliminary report; Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies: Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 lineages has led to the emergence of several new subvariants,… Read more ↓ https://t.co/vhYlJWmpeZ
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/5HV0XWN0oM #biorxiv_micrbio
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies https://t.co/k3CHU39TZA #bioRxiv
FG